A share price of Neumora Therapeutics Inc [NMRA] is currently trading at $2.86, up 4.00%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NMRA shares have gain 9.16% over the last week, with a monthly amount glided 58.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on October 27, 2025, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, JP Morgan downgraded its rating to Underweight on September 16, 2025. On April 02, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $1 on the stock. William Blair downgraded its rating to a Mkt Perform. Stifel downgraded its rating to a Hold and reduced its price target to $2 on March 07, 2025. Guggenheim downgraded its rating to Neutral for this stock on March 07, 2025. In a note dated January 02, 2025, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $29 to $4.
Neumora Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.61 and $13.05. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $2.86 at the most recent close of the market. An investor can expect a potential return of 179.72% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.33, Equity is -1.14 and Total Capital is -1.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.74 points at the first support level, and at 2.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.99, and for the 2nd resistance point, it is at 3.12.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neumora Therapeutics Inc [NASDAQ:NMRA] is 6.85. As well, the Quick Ratio is 6.85, while the Cash Ratio is 4.99.
Transactions by insiders
Recent insider trading involved Aurora Family Trust, Director, that happened on Nov 11 ’25 when 0.11 million shares were purchased. Director, Burow Kristina completed a deal on Oct 27 ’25 to buy 1.92 million shares. Meanwhile, 10% Owner ARCH Venture Partners XII, LLC bought 1.92 million shares on Oct 27 ’25.
